Cantargia ABCHIX:CANTAS 37 FCF Margin % is -5,109.45% as of Mar. 2026. GuruFocus rates CHIX:CANTAS with a GF Score™ of 37/100. The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, Cantargia AB ranks better than 96.77% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cantargia AB's Free Cash Flow for the
three
months ended in Mar. 2026 was kr-26.0 Mil. Cantargia AB's Revenue for the
three
months ended in Mar. 2026 was kr0.5 Mil. Therefore, Cantargia AB's FCF Margin % for the quarter that ended in Mar. 2026 was -5,109.45%.
The historical rank and industry rank for Cantargia AB's FCF Margin % or its related term are showing as below:
CHIX:CANTAs'
s FCF Margin % Range Over the Past 10 Years
Min: 47.26 Med: 47.26 Max: 49.68
Current: 49.68
During the past 13 years, the highest FCF Margin % of Cantargia AB was 49.68%. The lowest was 47.26%. And the median was 47.26%.
CHIX:CANTAs's FCF Margin % is ranked better than 96.77% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs CHIX:CANTAs: 49.68
Cantargia AB FCF Margin % Related Terms
Cantargia AB FCF Margin % Historical Data
* Premium members only.
The historical data trend for Cantargia AB's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:CANTAS vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Cantargia AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cantargia AB FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cantargia AB's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Cantargia AB's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cantargia AB (CHIX:CANTAS) has a FCF Margin % of -5,109.45% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cantargia AB and its competitors. Over the past decade, Cantargia AB's FCF Margin % has ranged from 47.26 to 49.68. According to the industry distribution chart, Cantargia AB ranks #31 out of 959 companies in the Biotechnology industry, placing it in the top 3.2%.
Is Cantargia AB's FCF Margin % too high?
Cantargia AB's current FCF Margin % is -5,109.45%. Over the past 10 years, this metric has ranged from a low of 47.26 to a high of 49.68. Based on the distribution chart, Cantargia AB ranks #31 out of 959 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cantargia AB has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Cantargia AB's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cantargia AB ranks #31 out of 959 companies for FCF Margin %. This places Cantargia AB in the top 3% of its industry — outperforming the majority of peers. Historically, Cantargia AB's own FCF Margin % has ranged from 47.26 to 49.68 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cantargia AB and its competitors. Cantargia AB's current FCF Margin % is -5,109.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantargia AB stock overvalued right now?
Cantargia AB (CHIX:CANTAS) has a current FCF Margin % of -5,109.45%. The current FCF Margin % is -5,109.45%. Cantargia AB's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Cantargia AB (CHIX:CANTAS), the current FCF Margin % is -5,109.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.
37GF Score
Get the complete analysis for CHIX:CANTAS
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CANTAS has been successfully added to your 
